Form 4 for NVCR NovoCure Ltd
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0001562180-25-002160 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-06 | 2025-03-04 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $18.19 | +55.0K | 221.2K | +33% | +$1000.0K |
| D | 2025-03-06 | 2025-03-04 | NVCR | Weinberg Uri | Chief Innovation Off | A - Grant | $18.19 | +81.5K | 81.5K | New | +$1.48M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-03-04 | A | A | 54,975 | $18.19 | 221,218 | D | — | — | (F1) Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. |
| 2 | Derivative | Stock Options (Right to buy) | 2025-03-04 | A | A | 81,499 | $18.19 | 81,499 | D | $18.19 · 2026-03-04 to 2035-03-03 | 81,499 Ordinary Shares | (F2) Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. |